MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Tempus AI, Inc. (NASDAQ:TEM)*
Organization & Developments: Tempus AI
Parents
Tempus AI, Inc. (NASDAQ:TEM)*
Children
*AI-powered genomic analysis for personalized mRNA vaccine design.
*Company connects with 2,500+ institutions to collect real-time clinical data on millions of cancer patients, enhancing treatment matching and clinical research
*Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.
*With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
202: Tempus AI in line for $200M from AstraZeneca, Pathos deal to develop cancer model
2024: Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation
2024: Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays
2024: Tempus AI: Why I'm Buying This AI Stock_seekingalpha.com
2024: Wall Street analysts bullish on genetic testing firm Tempus AI
2025: Boehringer teams up with Tempus AI to enhance cancer pipeline
2025: Decoding Tempus AI Inc (TEM): A Strategic SWOT Insight
2025: I'm Still Bullish On Tempus AI
2025: Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
2025: Personalis, Tempus Partner to Transform Early Cancer Detection for 150,000 Colorectal Cancer Patients Annually
2025: Sell Tempus AI Stock Before The Cooldown Hits
2025: Tempus AI Earnings: A Promising Business, But There Are Risks
2025: Tempus AI Has A High Probability Of Profitability In 2025
2025: Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector
2025: Tempus AI Receives FDA Clearance For Updated Tempus Pixel
2025: Tempus AI Reverses 192% Run. Why At Least One Analyst Remains A Believer.
2025: Tempus AI, Inc. (TEM) has received 510(k) clearance from the FDA for its updated Tempus Pixel, an AI-powered cardiac imaging platform
2025: Tempus AI: Bringing The Promise Of AI To Healthcare
2025: Tempus AI: Disappointing Q4 Preliminary Results, But Bullish Fundamental Update
2025: Tempus AI: Don't Be Blindly Optimistic On Anything AI
2025: Tempus AI: Firing On All Cylinders
2025: Tempus AI: Great Buying Opportunity On Recent Weakness (NASDAQ:TEM)
2025: Tempus AI: In Vogue, But Better To Wait For Some Retracement
2025: Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
2025: Tempus AI: Wait For A Cooldown
2025: Tempus AI: Why I'm Avoiding This Stock In 2025
2025: Tempus AI's Flywheel Effect: Monetizing Data In Precision Medicine_ seekingalpha.com
2025: Tempus Announces National Launch of olivia, its AI-enabled Personal Health Concierge App for Patients
2025: Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
2025: Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
2025: Tempus: Diagnostics Substance, AI Flash (NASDAQ:TEM)
2025: Tempus: Is This Ultra-Fast-Growing Company A Good Investment?
2025: TempusAI growth accelerates on genomics and data partnerships
2025: Why Tempus AI Is a Game-Changer
2026: 44th Annual J.P. Morgan Healthcare Conference (NASDAQ:TEM) 2026-01-12
2026: Tempus AI - J.P. Morgan Healthcare Conference Summary (January 2026)
2026: Tempus AI Expands Strategic Collaborations to Drive Future Growth
Jumps
Finance & Acquisition: Tempus AI
Key People: Tempus AI